JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2017, 66(3):117-126 | DOI: 10.36290/csf.2017.019

Effect of the vaginal pessaries Melanizol® and Klimedeks® on the glycogen level in the vaginal tissue of rats on the background of experimental vaginitis

Olena V. Dolzhykova1,*, Ludmyla M. Maloshtan1, Rimma F. Yeriomenko1, Volodymyr A. Maloshtan2
1 Department of Physiology and Human Anatomy, National University of Pharmacy (NUPh), Kharkiv, Ukraine
2 Department of Anaesthesiology and Intensive Care of the Kharkiv Medical Academy of Postgraduate Education

The experimental studies of the new vaginal pessaries Melanizol® and Klimedeks® have been carried out on the model of experimental vaginitis induced in rats by a mixture of terebenthine oil and dimethyl sulfoxide. The obtained experimental data indicate that the vaginal pessaries Melanizol® and Klimedeks® on the background of experimental vaginitis have a therapeutic effect on the 5th and 8th days of the experiment, significantly surpassing the group of animals of control pathology and placebo in its ability to restore physiological functions and accumulate glycogen by the vaginal epithelium. Melanizol® and Klimedeks® have significantly surpassed the reference drugs, the pessaries Gravagin® and Hippophaes oleum, but have been less efficient in the activity to the reference drug, the vaginal tablets Micogynax® on this criterion.

Keywords: glycogen; vaginal pessaries; vaginitis; rats

Received: March 17, 2017; Accepted: May 12, 2017; Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dolzhykova OV, Maloshtan LM, Yeriomenko RF, Maloshtan VA. Effect of the vaginal pessaries Melanizol® and Klimedeks® on the glycogen level in the vaginal tissue of rats on the background of experimental vaginitis. Čes. slov. farm. 2017;66(3):117-126. doi: 10.36290/csf.2017.019.
Download citation

References

  1. Atashili J., Poole C., Ndumbe P. M., Adimora A. A., Smith J. S. Bacterial vaginosis and HIV acquisition: A meta-analysis of published studies. AIDS 2008; 22(12), 1493-1501. Go to original source... Go to PubMed...
  2. Hill L. V. Vaginitis: current microbiologic and clinical concepts. CMAJ 1986; 134(4), 321-331.
  3. Burka O. A. One of the approaches in the treatment of inflammatory vaginitis. Newspaper "News of Medicine and Pharmacy". Obstetrics, gynecology, reproduction 2011; 381. http://www.mif-ua.com/archive/article_print/22944
  4. Boskey E. R., Cone R. A., Whaley K. J., Moench T. R. Origins of vaginal acidity: High D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod. 2001; 16(9), 1809-1813. Go to original source... Go to PubMed...
  5. Wilson W. A., Roach P. J., Montero M., Baroja-Fernández E., Muñoz F. J., Eydallin G., Viale A. M., Pozueta-Romero J. Regulation of glycogen metabolism in yeast and bacteria. FEMS Microbiol Rev. 2010; 34(6), 952-985. Go to original source... Go to PubMed...
  6. Mirmonsef P., Gilbert D., Veazey R. S., Wang J., Kendrick S. R., Spear G. T. A Comparison of Lower Genital Tract Glycogen and Lactic Acid Levels in Women and Macaques: Implications for HIV and SIV Susceptibility. AIDS Res. Hum. Retroviruses 2012; 28(1), 76-81. Go to original source... Go to PubMed...
  7. Yarnykh T. G., Levachkova Y. V., Maloshtan L. M., Stepanova K. O. Anti-inflammatory agent in the form of pessaries with metronidazole and tea tree oil: Patent. 96646 of Ukraine for invention; the applicant and patentee: National University of Pharmacy а 2010 01 134; announced on 04.02.2010; published on 25.11.2011, bull. N 22; 3.
  8. Stepanova K. O., Dolzhykova O. V., Maloshtan L. M., Levachkova Yu. V., Chushenko V. M., Yarnykh T. G. Preparation in the form of pessaries for treatment of infectious and inflammatory gynecological diseases: Patent 61038 of Ukraine for utility model; the applicant and patentee: National University of Pharmacy u 2010 13780; announced on 19.11.2010; published on 11.07.2011, bull. 13; 5.
  9. Sergienko А. V., Аlieva М. U., Sampieva К. Т., Ivashev М. N. Effects of Metronidazole and Likopid on experimental inflammation. Kuban scientific medical news. 2009; 8(113), 68-74.
  10. Chernichenko I. I. The use of Hippophaes oleum in gynecological practice. TERRA MEDICA 2006; 2, 26-29.
  11. European convention for the protection of vertebral animals used for experimental and other scientific purpose. Council of Europe 18.03.1986. Strasbourg 1986; 52.
  12. Nizhenkovska I. V., Pidchenko V. T., Bychkova N. G., Bisko N. A., Rodnichenko A. Y., Kozyko N. O. Influence of Ganoderma lucidum (Curt.: Fr.) P. Karst. on T-cell-mediated immunity in normal and immunosuppressed mice line CBA/Ca. Čes. slov. Farm. 2015; 64(4), 139-143. Go to original source...
  13. Rudko A. Y., Solntseva A. V., Usoieva L. A., Morugina L. V. Pharmaceutical composition for treatment of diseases of the urogenital organs: Patent 95741 of Ukraine for invention; the applicant and patentee: Public corporation "Nizhegorodskiy Chemical-Pharmaceutical Plant" а201010120; announced on 16.08.2010; published on 25.08.2011, bull. 16; 11.
  14. Rybolovliev Y. R., Rybolovliev R. S. Dosing substances for mammals according to the constants of biological activity. In: Reports of the USSR Academy of Sciences 1979; 247(6), 1513-1516.
  15. Meshkovoi N. P., Severina S. E. Method of determination of glucose and glycogen with anthrone. In: Practicum in biochemistry. Moscow: Publishing House of Moscow State University 1979; s. 41-43.
  16. Kononskii A. I. Histochemistry. Kiev: Vishha shkola 1976.
  17. Merkulov G. A. Histopathological technology course. Moscow: Medicine, Leningrad department 1969.
  18. Usov M. A. Clinical and diagnostic aspects of dysbiosis of vagina and treatment of bacterial vaginosis in women in early pregnancy: abstract of dissertation... candidate of medical sciences. Samara 2010; 24.
  19. Kent C. The Role of Glycogen in Vulvovaginal Health. https://wholewoman.com/blog/?p=1041 (1. 02. 2012).
  20. Mirmonsef P., Hotton A. L., Gilbert D., Burgad D., Landay A., Weber K. M., Cohen M., Ravel J., Spear G. T. Free Glycogen in Vaginal Fluids Is Associated with Lactobacillus Colonization and Low Vaginal pH. PLoS One 2014; 9(7)e102467, 1-11. Go to original source... Go to PubMed...
  21. Mirmonsef P., Hotton A. L., Gilbert D., Gioia C. J., Maric D., Hope T. J., Landay A. L., Spear G.T. Glycogen Levels in Undiluted Genital Fluid and Their Relationship to Vaginal pH, Estrogen, and Progesterone. PLoS One 2016; 11(4), e0153553. Go to original source... Go to PubMed...
  22. Badretdinova F. F., Mavzyutov A. R., Sheyda L. A., Kayumov F. A. Some aspects of determining the efficiency of therapy of vaginal dysbiosis in clinical conditions. Obstetrics and Gynecology 2015; 01(86), 92-93.
  23. Lester J., Pahouja G., Andersen B., Lustberg M. Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue. J. Pers. Med. 2015; 5, 50-66. Go to original source... Go to PubMed...
  24. Petrov Y. А. Mechanism of action contraceptive intrauterine device. International Journal of Applied and Fundamental Research 2016; 8, 724-726.
  25. Apolikhina I. A., Horbunova E. A. Clinical and morphological aspects of vulvovaginal atrophy. Obstetrics and gynecology. http://www.remedium.ru/doctor/gynaecology/detail.php?ID=67429 (19. 11. 2015).
  26. Dobrokhotova Y. E., Zatikian N. G. Hormone status and vaginal microbiocenosis. Obstetrics, gynecology, reproduction. 2008; 2(2), 7-9.
  27. Stika C. S. Atrophic vaginitis. Dermatol Ther 2010; 23, 514-522. Go to original source... Go to PubMed...
  28. Dennerstein G. J., Ellis D. H. Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol. 2001; 41(3), 326-328. Go to original source... Go to PubMed...
  29. Nunn K. L., Forney L. J. Unraveling the Dynamics of the Human Vaginal Microbiome. Yale J Biol Med. 2016; 89(3), 331-337.




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.